EA200501479A1 - Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией - Google Patents
Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменциейInfo
- Publication number
- EA200501479A1 EA200501479A1 EA200501479A EA200501479A EA200501479A1 EA 200501479 A1 EA200501479 A1 EA 200501479A1 EA 200501479 A EA200501479 A EA 200501479A EA 200501479 A EA200501479 A EA 200501479A EA 200501479 A1 EA200501479 A1 EA 200501479A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- ifn
- treatment
- combination
- alcheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к применению интерферона β (IFN-β) для лечения и/или предотвращения болезни Альцгеймера (AD), болезни Крейцфельда-Якоба (CJD) или болезни Герстманна-Штреусслера-Шейнкера (GSSD). Кроме того, оно относится к применению IFN-β в комбинации со средством для лечения болезни Альцгеймера для лечения и/или предотвращения болезни Альцгеймера. Предпочтительно применение IFN-β в комбинации с ингибитором холинэстеразы для лечения и/или предотвращения рано начинающейся болезни Альцгеймера.Отчет о международном поиске был опубликован 2005.01.13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03100716 | 2003-03-19 | ||
PCT/EP2004/050316 WO2004082706A2 (en) | 2003-03-19 | 2004-03-17 | Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200501479A1 true EA200501479A1 (ru) | 2006-02-24 |
EA009668B1 EA009668B1 (ru) | 2008-02-28 |
Family
ID=33016977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501479A EA009668B1 (ru) | 2003-03-19 | 2004-03-17 | Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070110715A1 (ru) |
EP (1) | EP1620124A2 (ru) |
JP (1) | JP2006520368A (ru) |
KR (1) | KR20050115279A (ru) |
CN (1) | CN1791423A (ru) |
AR (1) | AR043660A1 (ru) |
AU (1) | AU2004222529A1 (ru) |
BR (1) | BRPI0408491A (ru) |
CA (1) | CA2516990A1 (ru) |
EA (1) | EA009668B1 (ru) |
IL (1) | IL170751A0 (ru) |
MX (1) | MXPA05009986A (ru) |
NO (1) | NO20054744L (ru) |
WO (1) | WO2004082706A2 (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06011969A (es) * | 2004-04-14 | 2006-12-15 | Warner Lambert Co | Combinacion terapeutica para tratamiento de la enfermedad de alzheimer. |
US7695911B2 (en) | 2005-10-26 | 2010-04-13 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof |
JP2009531323A (ja) * | 2006-03-20 | 2009-09-03 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | アセチルコリンエステラーゼ阻害剤として有用な薬剤組成物 |
CN101116670B (zh) * | 2006-08-01 | 2010-11-10 | 广州和竺生物科技有限公司 | 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用 |
KR20090041447A (ko) * | 2006-08-21 | 2009-04-28 | 노파르티스 아게 | 알츠하이머 질환 진행에 대한 바이오마커 |
TWI432195B (zh) * | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
WO2010056622A1 (en) * | 2008-11-11 | 2010-05-20 | Targacept, Inc. | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS |
US20110081428A1 (en) * | 2009-09-16 | 2011-04-07 | The Buck Institute For Age Research | Use of thioflavin-like compounds to increase life span and/or health span |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
CN102382096A (zh) * | 2011-09-06 | 2012-03-21 | 清华大学 | 异香豆素及其衍生物的制备方法 |
CN102707065A (zh) * | 2012-03-23 | 2012-10-03 | 常熟市虞山绿茶有限公司 | Prohibitin蛋白抗体在制备诊断老年性痴呆的试剂盒中的应用 |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
US9116974B2 (en) * | 2013-03-15 | 2015-08-25 | Robert Bosch Gmbh | System and method for clustering data in input and output spaces |
CN106754995B (zh) * | 2016-11-25 | 2020-07-10 | 山东农业大学 | 中华蜜蜂AccCDK5基因及AccCDK5r1基因及其应用 |
RU2729391C2 (ru) * | 2018-12-28 | 2020-08-06 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Моноклональное антитело, способное нейтрализовать биологическую активность интерферона бета-1а человека |
CN109518211B (zh) * | 2019-01-08 | 2020-11-06 | 合肥工业大学 | 一种芳香偶酰类化合物的电化学合成方法 |
WO2023080687A1 (ko) * | 2021-11-03 | 2023-05-11 | 가천대학교 산학협력단 | 아밀로이드 베타 멀티머 저해 약물의 고속 대량 스크리닝 방법 및 독소루비신 또는 이의 유도체를 포함하는 아밀로이드 베타의 올리고머화 또는 섬유화 억제용 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000057879A1 (en) * | 1999-03-26 | 2000-10-05 | Barry Reisberg | Treatment of brain changes with myelin protective agents |
CA2393688A1 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
-
2004
- 2004-03-17 MX MXPA05009986A patent/MXPA05009986A/es unknown
- 2004-03-17 EA EA200501479A patent/EA009668B1/ru not_active IP Right Cessation
- 2004-03-17 JP JP2006505471A patent/JP2006520368A/ja active Pending
- 2004-03-17 BR BRPI0408491-8A patent/BRPI0408491A/pt not_active IP Right Cessation
- 2004-03-17 US US10/549,031 patent/US20070110715A1/en not_active Abandoned
- 2004-03-17 WO PCT/EP2004/050316 patent/WO2004082706A2/en active Application Filing
- 2004-03-17 KR KR1020057017076A patent/KR20050115279A/ko not_active Application Discontinuation
- 2004-03-17 AU AU2004222529A patent/AU2004222529A1/en not_active Abandoned
- 2004-03-17 CN CNA2004800135944A patent/CN1791423A/zh active Pending
- 2004-03-17 CA CA002516990A patent/CA2516990A1/en not_active Withdrawn
- 2004-03-17 EP EP04721198A patent/EP1620124A2/en not_active Withdrawn
- 2004-03-19 AR ARP040100921A patent/AR043660A1/es not_active Application Discontinuation
-
2005
- 2005-09-08 IL IL170751A patent/IL170751A0/en unknown
- 2005-10-14 NO NO20054744A patent/NO20054744L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1791423A (zh) | 2006-06-21 |
NO20054744L (no) | 2005-10-14 |
WO2004082706A3 (en) | 2005-01-13 |
BRPI0408491A (pt) | 2006-04-04 |
IL170751A0 (en) | 2011-08-01 |
KR20050115279A (ko) | 2005-12-07 |
JP2006520368A (ja) | 2006-09-07 |
MXPA05009986A (es) | 2005-11-04 |
EP1620124A2 (en) | 2006-02-01 |
WO2004082706A2 (en) | 2004-09-30 |
US20070110715A1 (en) | 2007-05-17 |
AR043660A1 (es) | 2005-08-03 |
CA2516990A1 (en) | 2004-09-30 |
AU2004222529A1 (en) | 2004-09-30 |
EA009668B1 (ru) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501479A1 (ru) | Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией | |
ES2170104T3 (es) | Inhibidores de la produccion de proteinas de beta-amiloide. | |
DE122008000046I1 (de) | Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes | |
GB0223040D0 (en) | Therapeutic compounds | |
BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
DE602004018338D1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
CY1108146T1 (el) | ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ | |
EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
CY1112932T1 (el) | Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς | |
EA200301253A1 (ru) | Применение остеопонтина для лечения и/или профилактики неврологических заболеваний | |
EA200401341A1 (ru) | Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания | |
DK1032556T3 (da) | Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder | |
SE0302304D0 (sv) | Novel compounds | |
EA200501528A1 (ru) | Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
ATE254595T1 (de) | 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten | |
EA200301299A1 (ru) | Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс | |
BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
EA200400296A1 (ru) | Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности | |
DE50003730D1 (de) | Caspase 8-inhibitoren zur immunsuppression | |
EA200501052A1 (ru) | Способ лечения поведенческих расстройств | |
DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
ES2132308T3 (es) | 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetil-piridina-3,5-dicarboxilato de isopropilo y 2-metoxietilo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |